Open Access<p>AT101-Loaded Cubosomes as an Alternative for Improved Glioblastoma Therapy</p>
Author(s) -
Dorota Flak,
Vivian Adamski,
Grzegorz Nowaczyk,
Kosma Szutkowski,
Michael Synowitz,
Stefan Jurga,
Janka HeldFeindt
Publication year - 2020
Publication title -
international journal of nanomedicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.245
H-Index - 128
eISSN - 1178-2013
pISSN - 1176-9114
DOI - 10.2147/ijn.s265061
Subject(s) - poloxamer , drug , chemistry , bioavailability , drug delivery , in vitro , pharmacology , cytotoxicity , apoptosis , cancer cell , biophysics , nanotechnology , materials science , cancer , biochemistry , medicine , biology , organic chemistry , copolymer , polymer
AT101, the R-(-)-enantiomer of the cottonseed-derived polyphenol gossypol, is a promising drug in glioblastoma multiforme (GBM) therapy due to its ability to trigger autophagic cell death but also to facilitate apoptosis in tumor cells. It does have some limitations such as poor solubility in water-based media and consequent low bioavailability, which affect its response rate during treatment. To overcome this drawback and to improve the anti-cancer potential of AT101, the use of cubosome-based formulation for AT101 drug delivery has been proposed. This is the first report on the use of cubosomes as AT101 drug carriers in GBM cells.